Clinical

Director, International Drug Information Center

Articles

In this article, we will review the evidence describing a possible link between vitamin D and COVID-19. 

Vitamin D and COVID-19: An Evidence-Based Review

Associate Clinical Professor, University of Connecticut School of Pharmacy, Storrs, CT.

On October 22, 2020, the FDA approved remdesivir (Veklury; Gilead) as the first treatment for coronavirus disease 2019 (COVID-19).

Remdesivir in the Treatment of COVID-19

Here are some of the top-read FDA approvals covered by Drug Topics® from this year.

Top FDA Approvals of 2020

Acetaminophen may be the antipyretic choice for many families, but a new study asks whether it could be a problem for children with asthma.

Journal Club: Acetaminophen for Fever in Children With Asthma

A poster presentation from ASHP Midyear 2020 Clinical Meeting & Exhibition highlighted the pharmacist’s role in improving outcomes in patients with COPD. 

Study: Pharmacy Care Plans to Reduce COPD Exacerbations

In a virtual session held during the ASHP Midyear 2020 Clinical Meeting & Exhibition, experts discussed updates in asthma management, including new data and upcoming guideline changes that will impact pharmacy practice.

Asthma Management: An Update on New and Upcoming Guidelines

A poster presented at the ASHP 2020 Midyear Clinical Meeting & Exhibition highlighted the success of an in-pharmacy pneumococcal immunization campaign. 

Independent Pharmacy-Led Pneumococcal Immunization Campaign Improves Vaccine Uptake

Pharmacists may be among the first of the prioritized groups to be offered the COVID-19 vaccine once it receives FDA authorization.  

ACIP: Prioritize Health Care Personnel, LTC Residents for COVID-19 Vaccination

Omalizumab (Xolair; Genentech and Novartis) is the first biologic approved for the treatment of nasal polyps that targets and blocks immunoglobulin E. 

FDA OKs Omalizumab for Maintenance Treatment of Nasal Polyps 

Interim analysis results from a phase 3 clinical trial reported a vaccine efficacy rate above 90% for BNT162b2. The trial is ongoing until it meets its threshold for confirmed COVID-19 cases.

Respiratory